Nivolumab + relatlimab
Checked 2026-09-09
Unresectable or metastatic melanoma, first line
One cycle
every 28 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Nivolumab + relatlimab (fixed dose) Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1) | 480 mg nivolumab / 160 mg relatlimab | IV | D1 |
Cycles
until progression
28-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Nivolumab + ipilimumab (melanoma)
Unresectable or metastatic melanoma, especially with brain metastases or PD-L1-negative disease
every 21 days × 4
Pembrolizumab monotherapy
Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)
every 21 days
Dabrafenib + trametinib
BRAF V600-mutant melanoma (adjuvant 1 year or metastatic), NSCLC, anaplastic thyroid cancer and tumour-agnostic use
every 28 days